News | May 08, 2022
Quality issues force Novartis to suspend production of radioligand therapy medicines
The production suspension impacts commercial and clinical trial supply
The production suspension impacts commercial and clinical trial supply
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Collaboration in the industry needs to be institutionalised to drive the growth.
Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Exclusive partnership introduces globally benchmarked stem cell processing platform aimed at improving stem cell recovery, quality, and long-term therapeutic potential
Collaboration integrates MERCURIUS DRUG-seq technologies with Revvity’s screening portfolio, enabling scalable transcriptomic profiling for next-generation drug discovery and AI-driven research
Production at Vadodara facility strengthens Make in India initiative, enhances access to diagnostic testing, and supports preventive healthcare across the country
Subscribe To Our Newsletter & Stay Updated
